RxDoctor Payments Data

Lillian Hunt, MD

Internal Medicine · Arlington, VANPI 1295791978

Payments from drug & device makers

$4,929in general payments, 2019–2025

Across 160 payments — averaging $30.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Vanda Pharmaceuticals Inc.$862
  • Otsuka America Pharmaceutical, Inc.$457
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$266
  • Astellas Pharma US Inc$199
  • Novo Nordisk$146
  • plus $402 from 10 others
$150in research payments, 2019–2025

Across 1 payment — averaging $150.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Indivior Inc.$150

What the payments were for

  • Food & beverage$4,80898%
  • Education$1212%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,929 in reported general payments places this provider in the 90th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$183,521
Medicare patients
149
Services billed
1,604

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl27$38,490
Candesartan Cilexetil81$8,196
Carvedilol ErCarvedilol Phosphate12$5,066
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl65$4,706
Levothyroxine Sodium173$4,130
PaxlovidNirmatrelvir/Ritonavir12$2,859
Irbesartan36$2,378
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$2,262
Olopatadine Hcl18$2,011
Atorvastatin Calcium187$1,972
Gabapentin166$1,854
Rosuvastatin Calcium44$1,604
Metoprolol Succinate54$1,420
Candesartan-HydrochlorothiazidCandesartan/Hydrochlorothiazid11$1,367
Montelukast Sodium62$1,171

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar, Synthroid$2,596$38,75938 claims
PfizerPaxlovid$18$2,85912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Arlington

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →